Catalog No.
Product Name
Application
Product Information
Citations
-
SARS-CoV-2 Mpro PROTAC Degrader
PROTAC SARS-CoV-2 Mpro degrader-2 is a highly effective PROTAC degrader targeting the main protease (Mpro) of SARS-CoV-2. This compound exhibits significant antiviral activity against various coronaviruses, including EC50 values of 10.8 μM for SARS-CoV-2, 1.6 μM for HCoV-OC43, and 6.5 μM for HCoV-229E. In Calu-3 cells, it demonstrates potent efficacy with an EC50 of 0.89 μM, making it a valuable tool for research focused on coronavirus biology and potential therapeutic interventions. -
E3 Ligase Ligand-linker Conjugate
E3 Ligase Ligand-linker Conjugate 214 is an innovative E3 ligase ligand-linker conjugate featuring a Von Hippel-Lindau (VHL) ligand. This compound effectively binds to target proteins, facilitating the formation of PROTAC (Proteolysis Targeting Chimeras) molecules, such as the PROTAC LSD1 Degrader 1. Its application in targeted protein degradation research supports the development of novel therapeutic strategies in cancer and other diseases. -
E3 Ligase Ligand and PROTAC Linker
(S)-Deoxy-thalidomide-2,7-diazaspiro[3.5]nonane-CH2-Me-PIP-Boc serves as an E3 ligase ligand and a PROTAC linker, facilitating targeted protein degradation. It is integral to the development of PROTAC K-Ras Degrader-3, demonstrating potential in cancer research. This compound is designed to help elucidate molecular mechanisms and therapeutic pathways involved in oncogenesis. -
ASK1 PROTAC Degrader
dASK1 is a selective PROTAC degrader targeting apoptosis signal-regulating kinase 1 (ASK1) through a cereblon (CRBN)-mediated pathway. This compound forms a stable ternary complex with ASK1, promoting its efficient degradation via the ubiquitin-proteasome system. dASK1 exhibits potent activity in degrading ASK1 and serves as a valuable tool in research focused on steatohepatitis and related pathologies. -
MYC Molecular Glues Degrader
MYC Degrader 1 is a potent molecular glue degrader that targets the MYC oncogene, facilitating the degradation of MYC proteins. This compound exhibits significant anti-tumor activity by restoring the functionality of the pRB1 protein, thereby reinstating the sensitivity of MYC-overexpressing cancer cells to CDK4/6 inhibitors. MYC Degrader 1 is suitable for research applications focusing on cancer therapeutics and the modulation of MYC-driven signaling pathways. -
CDK9 PROTAC Degrader
KI-CDK9d-32 is a selective and potent degrader designed to target CDK9 through a PROTAC mechanism (DC50: 0.89 nM). It facilitates the ubiquitination and subsequent degradation of CDK9, effectively inhibiting the MYC signaling pathway and disrupting nucleolar homeostasis. This compound demonstrates significant anticancer activity, particularly against acute lymphoblastic leukemia and pancreatic cancer, making it a valuable tool for research in cancer biology and therapeutic development. -
DAPK1 PROTAC Degrader
PROTAC DAPK1 Degrader-1 selectively targets DAPK1 for degradation, exhibiting a DC50 value of 119.6 nM. This compound has been shown to elevate MDM2 protein levels while concurrently decreasing cleaved caspase-3 and cleaved PARP levels in a neurotoxin-induced cell apoptosis model. Its ability to effectively inhibit neuronal apoptosis positions PROTAC DAPK1 Degrader-1 as a valuable tool for investigating neurological disorders, including cerebral ischemia and traumatic brain injury. -
PROTAC Degrader for FKBP12
22-SLF is a PROTAC degrader specifically targeting FK506-binding protein 12 (FKBP12), exhibiting a DC50 of 0.5 µM. This compound forms a ternary complex with C227 and C228 in FBXO22, facilitating FKBP12 degradation in an FBXO22-dependent manner. 22-SLF is a valuable tool for cancer research, serving as a probe to investigate the FBXO22-mediated degradation pathways. -
Ligands for Target Protein for PROTAC
POI ligand-2 is a specific ligand for the GPX4 protein, facilitating targeted protein degradation. This compound is instrumental in the synthesis of PROTACs, including PROTAC GPX4 degrader-5. Its application in protein research enables efficient modulation of GPX4 levels, aiding studies in mechanistic biology and therapeutic interventions targeting oxidative stress pathways. -
EZH2 PROTAC
PROTAC EZH2 Degrader-41 is a PROTAC designed to target EZH2 by recruiting cIAP E3 ubiquitin ligase. This compound facilitates the ubiquitination and subsequent proteasomal degradation of EZH2, thereby exerting significant antiproliferative effects in lymphoma cells. PROTAC EZH2 Degrader-41 is a valuable tool for investigating the role of EZH2 in lymphoma research and its potential as a therapeutic target. -
PROTAC MDM2 degrader
YX-02-030 is a PROTAC MDM2 degrader that effectively inhibits the MDM2-p53 interaction with an IC50 value of 63 nM, as well as the VHL-HIF1α binding, with an IC50 of 1.35 μM. By binding to MDM2, it recruits the VHL E3 ubiquitin ligase, promoting MDM2 degradation. This compound is particularly relevant in researching therapeutic strategies against p53 mutant or deleted triple-negative breast cancer (TNBC) cells. -
TAF1 PROTAC Degrader
ZS3-046 is a TAF1 PROTAC degrader that facilitates the ubiquitination and subsequent degradation of the TAF1 protein. This compound effectively activates p53, leading to apoptosis in acute myeloid leukemia (AML) cells. In vivo studies have demonstrated its antitumor efficacy in AML tumor xenograft mouse models, making ZS3-046 a valuable tool for researching targeted degradation strategies in cancer therapy. -
MDM2 Degrader
MD-265 is a potent MDM2 degrader utilizing the PROTAC (PROteolysis TArgeting Chimeras) technology. It effectively promotes the degradation of MDM2, resulting in the reactivation of the p53 tumor suppressor pathway in cancer cells with wild-type p53. Preclinical studies demonstrate that MD-265 induces complete tumor regression and enhances long-term survival in leukemia models, making it a valuable tool for cancer research and therapeutic development. -
Hemagglutinin Degrader
PROTAC Hemagglutinin Degrader-1 is a potent degrader specifically targeting influenza hemagglutinin (HA). It exhibits significant biological activity with a median degradation concentration of 1.44 μM, demonstrating broad-spectrum efficacy against influenza viruses. This compound is valuable for research applications focused on viral suppression and the development of antiviral therapeutic strategies. -
HIV-1 Nef Binder, IKZF1 Modulator
FC-14369 is a PROTAC degrader that selectively targets the HIV-1 Nef protein, exhibiting a DC50 value of 160 nM. By engaging both Nef and the Cereblon E3 ubiquitin ligase, FC-14369 facilitates the ubiquitination and subsequent proteasomal degradation of Nef, leading to the restoration of CD4 and MHC-I expression on the cell surface and effectively inhibiting HIV-1 replication. This compound is valuable for research focused on HIV infection and AIDS, advancing understanding of therapeutic strategies in viral infections. -
PROTAC Degrader
FC-14367 is a PROTAC degrader that selectively targets the HIV-1 Nef protein. It facilitates the formation of a ternary complex by simultaneously binding to Nef and Cereblon E3 ubiquitin ligase, leading to the ubiquitination and subsequent proteasomal degradation of Nef. This process restores the surface expression of CD4 and MHC-I molecules while effectively inhibiting HIV-1 replication. FC-14367 is valuable for research focused on HIV infection and AIDS pathogenesis. -
Ligands for E3 Ligase
Nef ligand-2 is a specific ligand for the Nef protein, functioning primarily as a binder that targets E3 ligases. It plays a crucial role in modulating protein interactions and degradation pathways, offering valuable insights into Nef-related signaling mechanisms. This compound is particularly relevant in research applications focused on HIV pathogenesis and the exploration of therapeutic strategies targeting E3 ligase activity. -
eDHFR PROTAC
PROTAC eDHFR Degrader-2 selectively targets Escherichia coli dihydrofolate reductase (eDHFR) for degradation. By utilizing a PROTAC mechanism, this compound efficiently promotes the degradation of eDHFR-tagged proteins, making it a valuable tool for studies in protein regulation and degradation pathways. Its ability to modulate protein levels can aid in the investigation of various biological processes and contribute to the development of therapeutic strategies. -
CCR2 PROTAC Degrader
LUF7996 is a potent CCR2 PROTAC degrader that selectively targets and degrades CCR2 with a DC50 value of 2.6 μM. This compound effectively engages with the E3 ligase cereblon, promoting sustained and concentration-dependent degradation of CCR2 via the lysosomal pathway. LUF7996 is particularly valuable for research applications involving the inhibition of monocyte migration in vitro, facilitating studies in inflammation and immune response modulation. -
α1A-AR Degrader
α1A-AR Degrader 9c is a selective, reversible degrader specifically targeting the α1A-adrenergic receptor (α1A-AR) through the proteasomal degradation pathway. It demonstrates significant biological activity, inhibiting the proliferation of PC-3 cells with an IC50 value of 6.12 μM. This compound is valuable for research applications in prostate cancer, providing insights into the therapeutic potential of α1A-AR degradation in oncology studies. -
PROTAC BRD4 Degrader
L134 is a potent PROTAC BRD4 degrader that targets BRD4 for ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway, demonstrating a DC50 value of 7.36 nM. This compound operates in a DCAF11-dependent manner, making it a valuable tool for studying BRD4-related signaling and therapeutic applications in cancer and other diseases. As a versatile reagent, L134 supports research in targeted protein degradation and the modulation of gene expression pathways. -
p300/CBP Degrader
MJP6412 is a selective degrader of the histone acetyltransferases p300 and CBP, exhibiting DC50 values of 1.6 nM and 1.2 nM, respectively. This compound effectively induces degradation of these proteins, thereby modulating acetylation levels in cells. MJP6412 is particularly relevant in cancer research, providing insights into the role of p300 and CBP in oncogenic processes and potential therapeutic interventions. -
PROTAC KDM5B Degrader
GT-653 is a PROTAC degrader targeting lysine-specific demethylase 5B (KDM5B). It efficiently induces degradation of KDM5B by 68.35% at a concentration of 10 μM through a ubiquitin proteasome-dependent mechanism. This compound elevates H3K4me3 levels and activates type-I interferon signaling pathways in prostate cancer cells, specifically in the 22RV1 cell line. Research applications include studying KDM5B's role in cancer biology and evaluating potential therapeutic strategies that involve epigenetic modulation. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-12 is a CRBN-recruiting PROTAC designed to selectively degrade the EZH2 protein, exhibiting an IC50 of 3.90 nM for EZH2 and an IC50 of 5.24 μM for EZH1. This compound facilitates targeted protein degradation, making it a valuable tool for research focused on epigenetic regulation and cancer biology. Its ability to modulate the expression of key oncogenic factors positions it as a significant reagent for therapeutic investigations targeting EZH2-dependent pathways. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-24 is an innovative molecule designed to target EZH2 by utilizing a PROTAC-mediated degradation mechanism. This compound exhibits potent EZH2 methyltransferase inhibitory activity, facilitating the selective degradation of the EZH2 protein. Research applications include studies on epigenetic regulation and therapeutic strategies for cancers with aberrant EZH2 activity. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-30 is a PROTAC protein degrader specifically designed to target the enhancer of zeste homolog 2 (EZH2) with an IC50 of 6.22 μM in SU-DHL-6 cells. This compound is instrumental in research applications focusing on diffuse large B-cell lymphoma by promoting the degradation of EZH2 and thereby modulating epigenetic regulation. The inclusion of ligands for both EZH2 and MDM2, coupled with a linker, facilitates targeted protein degradation and offers a valuable tool for investigating therapeutic strategies in cancer biology. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-43 is a targeted PROTAC protein degrader that specifically degrades the EZH2 protein, exhibiting an IC50 of 21.73 μM in SU-DHL-6 cells. This compound is valuable for investigating the role of EZH2 in lymphoma research and understanding its mechanistic function in histone methylation. The dual ligand design incorporates a histone methyltransferase ligand and a VHL ligand, promoting efficient substrate recognition and recruitment for proteasomal degradation. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-17 is a selective protein degrader that targets the enhancer of zeste homolog 2 (EZH2). This compound demonstrates significant antiproliferative activity, with an IC50 of 18.32 μM in lymphoma cell lines. PROTAC EZH2 Degrader-17 is a valuable tool for investigating EZH2-related pathologies and provides insights into the therapeutic potential of protein degradation in cancer research. -
EZH2 Ligand
EZH2 ligand-3 functions as a ligand targeting the Enhancer of Zeste Homolog 2 (EZH2) protein. This compound plays a crucial role in the synthesis of PROTAC EZH2 Degrader-35, facilitating the selective degradation of EZH2 in cellular models. It is valuable for research applications focused on epigenetic regulation and targeted protein degradation strategies. -
EZH2 PROTAC
PROTAC EZH2 Degrader-26 is a targeted proteolysis-targeting chimera (PROTAC) designed to specifically degradation of the enhancer of zeste homolog 2 (EZH2). This compound demonstrates a potent inhibitory activity with an IC50 of 5.80 nM against EZH2, alongside micromolar-level activity against EZH1, with an IC50 of 0.06 μM. PROTAC EZH2 Degrader-26 is suitable for research applications involving epigenetic regulation, cancer biology, and studies aimed at understanding histone methylation processes. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-39 is a targeted PROTAC that effectively degrades the EZH2 protein, exhibiting an IC50 of 61.00 nM. This compound functionally inhibits the methyltransferase activity of EZH2, making it an important tool for studying the biological implications of EZH2 modulation. Its applications include cancer research and epigenetic regulation studies, contributing to advancements in targeted therapy development. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-15 is a targeted degrader that specifically interacts with the EZH2 protein via a proteolysis-targeting chimera (PROTAC) mechanism. This compound effectively inhibits the methyltransferase activity of EZH2, leading to its degradation and resulting in alterations to histone methylation patterns. It serves as a valuable tool for research applications focused on epigenetic regulation, cancer biology, and therapeutic strategies aimed at EZH2 modulated pathways. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-10 is a Proteolysis Targeting Chimeras (PROTAC) compound designed to selectively degrade the enhancer of zeste homolog 2 (EZH2). By facilitating the ubiquitination and subsequent proteasomal degradation of EZH2, this compound exhibits potential as an innovative therapeutic approach for cancer research. Its mechanism involves a specific ligand for EZH2 and a cereblon ligand, linked together to enhance degradation efficiency, making it a valuable tool for investigating EZH2-related oncogenic pathways. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-35 is a proteolysis-targeting chimera (PROTAC) specifically designed to degrade the Enhancer of Zeste Homolog 2 (EZH2) protein, exhibiting a binding affinity (Ka) of 16.19 nM. This compound demonstrates significant antiproliferative activity against triple-negative breast cancer cells while maintaining minimal cytotoxicity toward normal human epithelial, hepatic, and renal cells. PROTAC EZH2 Degrader-35 is a valuable tool for studying the role of EZH2 in cancer biology and has potential applications in therapeutic research focused on triple-negative breast cancer. -
EZH2 PROTAC
PROTAC EZH2 Degrader-27 is a potent EZH2 PROTAC inhibitor with an IC50 of 4.00 nM, specifically designed to target the SET domain of the EZH2 methyltransferase. By engaging in targeted protein degradation, this compound effectively inhibits methyltransferase activity, leading to downregulation of histone methylation. Research applications include studies on epigenetic regulation and potential therapeutic strategies targeting EZH2 in various cancers. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-13 is a targeted proteolysis-targeting chimera (PROTAC) designed to selectively degrade Enhancer of Zeste Homolog 2 (EZH2) with an IC50 of 2.70 nM. This compound exhibits potent antiproliferative effects in various cancer cell lines, making it a valuable tool in cancer research. PROTAC EZH2 Degrader-13 facilitates investigations into the role of EZH2 in tumorigenesis and therapeutic resistance, providing insights for the development of innovative cancer treatments. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-23 is a targeted protein degradant that specifically degrades EZH2 through a PROTAC mechanism. It acts by inhibiting the methyltransferase activity of EZH2 via binding to the SET domain, exhibiting a target IC50 of 30.00 nM. This compound is valuable for research applications focused on the modulation of gene silencing pathways and the exploration of EZH2's role in cancer biology. -
PRMT5/MEP50 complex Degrader
MS115 is a selective degrader targeting the PRMT5/MEP50 complex, demonstrating DC50 values of 17.4 nM and 11.3 nM for PRMT5 at 24 hours in MDAMB468 breast cancer cells. This compound effectively inhibits the proliferation of breast cancer cells, making it a valuable tool for studying PRMT5-mediated pathways and evaluating therapeutic strategies in cancer research. MS115's unique mechanism positions it as a significant reagent for investigating the roles of epigenetic regulators in tumor biology. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-37 is a PROTAC compound designed to induce the degradation of the EZH2 protein, exhibiting a target IC50 of 144 nM. This reagent is valuable for research related to lymphomas and other conditions where dysregulation of histone methylation is implicated. Its mechanism harnesses the cellular degradation pathway, providing a potent tool for studying EZH2-dependent biological processes and developing therapeutic strategies against EZH2-driven malignancies. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-28 is a targeted PROTAC protein degrader designed to selectively degrade the EZH2 enzyme, demonstrating an IC50 of 16.2 μM in diffuse large B-cell lymphoma (DLBCL) cell lines. This compound is valuable for studying the role of EZH2 in lymphoma biology and therapeutic interventions. Its dual-ligand structure combines an EZH2 ligand with a VHL ligand, facilitating targeted protein degradation for advancing cancer research. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-20 is a small-molecule degrader specifically designed to target the EZH2 protein, utilizing the proteolysis targeting chimera (PROTAC) mechanism. It demonstrates potent antiproliferative effects with an IC50 of approximately 10 μM in lymphoma cell lines. This compound is ideal for research focused on understanding the role of EZH2 in lymphoma and exploring new therapeutic approaches for this malignancy. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-25 is a proteolysis-targeting chimera (PROTAC) designed to specifically degrade the EZH2 protein through targeted ubiquitination and proteasomal degradation. This compound is valuable for investigating the role of EZH2 in various lymphoma types, facilitating studies on its contribution to tumorigenesis. In addition, it illustrates the potential of PROTAC technology in modulating epigenetic regulators for therapeutic applications. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-16 is a targeted PROTAC protein degrader that specifically induces the degradation of EZH2, exhibiting an IC50 of 13.74 μM in SU-DHL-6 cells. This compound demonstrates significant antiproliferative activity against diffuse large B-cell lymphoma (DLBCL) cells, making it valuable for research focused on DLBCL. Its unique design incorporates a histone methyltransferase ligand and a Cereblon ligand linked via a proprietary linker, facilitating targeted degradation for therapeutic exploration. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-31 is a targeted protein degrader that effectively interacts with EZH2, promoting its degradation through the use of a PROTAC strategy. This compound demonstrates potent antiproliferative activity, with IC50 values of 3.63 μM in lSU-DHL-6 cells and 8.74 μM in HBL-1 cells. It is valuable for research focused on lymphoma, offering insights into EZH2-mediated pathways and potential therapeutic interventions. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-14 is an EZH2-targeting PROTAC degrader that selectively induces degradation of the EZH2 protein. With an IC50 of 18.21 μM, it effectively targets diffuse large B-cell lymphoma cells while showing no antiproliferative effects on non-target cells at concentrations up to 30.00 μM. This compound is valuable for research focused on the role of EZH2 in diffuse large B-cell lymphoma and provides a tool for exploring novel therapeutic strategies in oncology. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-22 is a PROTAC (Proteolysis Targeting Chimera) designed to target and degrade the EZH2 protein. This compound effectively modulates EZH2 activity, leading to the inhibition of histone methylation and promoting cancer cell apoptosis. It is particularly valuable in cancer-related research, facilitating the study of epigenetic regulation and therapeutic interventions. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-42 is a targeted degrader that specifically induces degradation of EZH2, a histone methyltransferase, via cIAP-mediated ubiquitination and subsequent proteasomal pathway. This compound exhibits antiproliferative activity and is particularly useful in the study of lymphoma. By modulating EZH2 levels, it provides a valuable tool for investigating epigenetic regulation and related therapeutic strategies in cancer research. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-36 is a targeted PROTAC designed to degrade the EZH2 protein, exhibiting a target IC50 of 16.00 nM. This compound is particularly relevant for research applications related to lymphoma, leveraging the selective degradation of EZH2 to investigate its role in cancer progression. The molecule consists of a histone methyltransferase ligand, a Cereblon ligand, and a linker, facilitating the ubiquitin-proteasome pathway for protein elimination. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-19 is a potent PROTAC compound that targets the enhancing zeste homolog 2 (EZH2) with an IC50 of 15.00 nM. This reagent effectively induces degradation of all Polycomb Repressive Complex 2 (PRC2) subunits, including EZH2, SUZ12, EED, and RbAp48, in a concentration- and time-dependent manner. PROTAC EZH2 Degrader-19 demonstrates significant antiproliferative effects in cancer cell lines, making it a valuable tool for cancer research and therapeutic applications. -
EZH2 PROTAC Degrader
PROTAC EZH2 Degrader-34 is a targeted degrader of EZH2, exhibiting an IC50 of 6.30 μM in human EZH2 inhibition. This compound is designed to selectively induce the degradation of EZH2, a key enzyme involved in histone methylation. Its applications are primarily in the study of malignancies such as Pfeiffer and prostate cancer, facilitating investigations into the molecular mechanisms of oncogenesis and potential therapeutic interventions.
